ARCALIS is pleased to announce the launch of a small-scale, High‑Throughput mRNA / LNP manufacturing service specialized for early-stage research and screening purposes, effective April 20, 2026.

This service is designed for researchers seeking to efficiently evaluate multiple mRNA sequences and LNP formulations. Leveraging an automated platform, we offer a manufacturing setup optimized for small-batch, multi-sample production.

By enabling rapid decision-making in early research phases, including lead identification, sequence optimization, and formulation screening, this service provides a seamless solution to bridge initial research activities to the next stage of development.